tailieunhanh - báo cáo khoa học:" Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study | Jongen et al. Health and Quality of Life Outcomes 2010 8 133 http content 8 1 133 HEALTH AND QUALITY of life outcomes RESEARCH Open Access Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate a prospective observational international multi-centre study Pofor I l itinon 1 irk I 2 hnir lv2 p orf sgnHorc3 Pioroffo oolHrgx orc4 Prorlrilvcmn5 Mgnm IC A nrlorccmn6 reter J JUIIUcll Dll Lclllc even jdlieib Pierette jeeidyeib Dtei I FieillxbUII IVIdUHUb nlieibbUII Joachim Speck7 FOCUS study group Abstract Background Glatiramer acetate GA aid iHterferoH-beta INFb are first-liie disease modifyiig drugs for relapsiig remittiig multiple sclerosis RRMS . Treatmeit with INFb is associated with a sigiificait iicrease ii health-related quality of life HR-QoL ii the first 12 moiths. It is iot kiowi whether HR-QoL iicreases duriig treatmeit with GA. Methods 197 RRMS patieits 106 without aid 91 with prior immuiomodulatioi immuiosuppressioi were studied for HR-QoL Leeds Multiple Sclerosis-QoL LMS-QoL scale score raige 0 - 32 fatigue Fatigue Impact Scale FIS aid depressed mood Beck Depressioi liveitory-Short Form BDI-SF at baseliie aid 6 aid 12 moiths after start of GA treatmeit. Results At 6 aid 12 moiths meai LMS-QoL scores were sigiificaitly iicreased ii the treatmeit-iaive patieit group p iot ii the pre-treated group. At moith 12 43 of treatmeit-iaive patieits had Improved HR-QoL Iicrease LMS-QoL score 3 or more poiits p . Likewise meai FIS scores were decreased at moiths 6 aid 12 ii the treatmeit-iaive group p iot ii the pre-treated group. Ii both groups meai BDI-SF scores did iot chaige. No demographic or cliiical baseliie factor was predictive of HR-QoL Iicrease. HR-QoL chaiges were zero to iegative for patieits who had discoitiiued GA before moith 12 of patieits . Conclusions Ii RRMS patieits without prior ImmuiomodulatIoi ImmuiosuppressIoi treatmeit with GA was associated .